Precision BioSciences, Inc.

CMN Weekly (4 October 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (16 August 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (2 August 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (5 July 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (10 May 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (29 March 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Clinical Trial Updates From the Gene-Editing Field...

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

CMN Weekly (1 March 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Precision BioSciences, Inc.

Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study (NCT05822427)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

B-Cell Non-Hodgkin Lymphoma, NHL, (NCT04649112)
Sponsors:
Precision BioSciences Inc.

IND Enabling

Phase I

Phase II

Phase III

B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT03666000)
Sponsors:
Imugene Limited

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT04171843)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Lymphoma and Leukaemia, (NCT04030195)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Search CRISPR Medicine